After an embryo transfer, most patients receive a prescription for progesterone — typically as vaginal pessaries, an injection, or oral tablets — and are told to take it every day until the pregnancy test and, if the test is positive, for several weeks into the first trimester. This medication — often taken for granted as a routine component of the post-transfer protocol — is actually one of the most clinically important elements of the entire IVF cycle.
Yet despite its importance, the explanation most patients receive for why they are taking progesterone after an embryo transfer is usually brief: "it supports the uterine lining" or "it helps with implantation." These explanations are not wrong — but they are incomplete. They do not explain why progesterone is necessary in an IVF cycle when it is produced naturally in a non-IVF cycle. They do not explain what happens if the medication is missed or stopped too early. And they do not address the important practical questions about route of administration, dose, and how long supplementation should continue.
This article provides the complete explanation. What the luteal phase is and what it requires. Why IVF disrupts natural luteal phase function and why supplementation is necessary. How different progesterone preparations compare. What the dose and duration of supplementation should be. And what happens — in both directions — if the progesterone component of the post-transfer protocol is not managed correctly.
What Is the Luteal Phase?
The menstrual cycle is divided into two phases by ovulation. The follicular phase is the first half — from the start of the period to ovulation — during which a follicle develops in the ovary under the influence of FSH, growing to dominance, and releasing its egg at ovulation. The luteal phase is the second half — from ovulation to the start of the next period — during which the body prepares for the possibility of pregnancy.
At ovulation, the follicle that releases the egg collapses inward and transforms into a specialized structure called the corpus luteum. The corpus luteum — which means "yellow body" in Latin — is a temporary endocrine gland that immediately begins producing progesterone in substantial quantities.
Progesterone is the essential hormone of the luteal phase. Its functions in the context of fertility are multiple and critical.
Endometrial maturation. During the follicular phase, rising estrogen caused the endometrium to proliferate — to grow thicker and more vascularized. Progesterone transforms this proliferative endometrium into a secretory endometrium — one that is ready to receive and nurture an implanting embryo. The glands in the secretory endometrium produce nutrients for the embryo. The stroma — the supporting tissue — undergoes decidualization, developing the specialized cells that will eventually form the maternal component of the placenta.
The implantation window. Progesterone triggers the opening of the implantation window — the specific period during which the endometrium is receptive to an embryo. This window opens approximately five to seven days after ovulation (or after progesterone initiation in a medicated cycle) and remains open for approximately forty-eight to seventy-two hours. Embryos transferred outside this window — before or after it opens — cannot implant effectively.
Immunological tolerance. Progesterone plays a role in modulating the immune environment of the endometrium — creating the immunological tolerance necessary for the embryo (which carries paternal genetic material and is therefore partially foreign to the mother's immune system) to implant without being rejected.
Pregnancy maintenance. If implantation occurs, the developing trophoblast — the embryo's earliest placental tissue — begins producing hCG. This hCG stimulates the corpus luteum to continue producing progesterone rather than undergoing its natural regression, which would otherwise occur approximately fourteen days after ovulation. The progesterone from the sustained corpus luteum maintains the endometrium and the pregnancy through the first weeks until the placenta matures sufficiently to take over progesterone production — a transition that typically completes around ten to twelve weeks of gestation.
In a natural cycle, this entire system operates autonomously. The corpus luteum forms at ovulation, produces progesterone in appropriate quantities, and is either rescued by hCG if pregnancy occurs or regresses if it does not. The body handles the luteal phase without external intervention.
In an IVF cycle, this autonomous system is disrupted — and that disruption is the reason progesterone supplementation is necessary.
Why IVF Disrupts Natural Luteal Phase Function
The egg retrieval procedure in an IVF cycle — the aspiration of follicular fluid from each follicle using an ultrasound-guided needle — does not just collect eggs. It also removes a significant portion of the granulosa and theca cells that surround each follicle and that would, after ovulation, form the corpus luteum.
In a natural cycle, the cells of the dominant follicle transform into the corpus luteum at ovulation. In an IVF cycle, many of these cells are removed at retrieval. The result is a corpus luteum — or, more accurately, multiple small luteal structures from each retrieved follicle — that is functionally compromised. The post-retrieval luteal phase in an IVF cycle is characterized by inadequate progesterone production relative to what a normal corpus luteum would provide.
Additionally, the GnRH analogs used in many IVF protocols — either agonists (in the long downregulation protocol) or antagonists (in the antagonist protocol) — suppress pituitary LH production. Since LH is the signal that maintains corpus luteum function throughout the luteal phase, pituitary suppression further compromises the luteal phase in stimulated IVF cycles.
The consequence of this compromised luteal phase is an endometrial environment that, without external progesterone support, may not be adequately transformed for implantation and may not be maintained for the duration required for early pregnancy to establish.
The solution is luteal phase support — the external administration of progesterone to compensate for the inadequate corpus luteal function of the post-retrieval cycle.
In frozen embryo transfer cycles, the rationale is even more direct: the FET cycle involves no fresh ovulation and no corpus luteum at all — the entire luteal phase is artificially created through external hormone administration. Progesterone supplementation in an artificial FET cycle is not support for a compromised natural luteal phase — it is the entire luteal phase, created from scratch.
Forms of Progesterone Supplementation
Progesterone for luteal support is available in several different formulations — each with its own route of administration, pharmacokinetics, and clinical indications. Understanding the differences helps explain why specific preparations are chosen for specific situations.
Vaginal Progesterone — the Most Widely Used
Vaginal progesterone — typically as pessaries (suppositories), gels, or capsules inserted vaginally — is the most widely used form of luteal support in IVF globally. Its primary advantage is the "first uterine pass effect" — vaginal progesterone is absorbed through the vaginal mucosa and transported directly to the uterus, producing high local endometrial progesterone concentrations with relatively low systemic blood levels. This means that the uterine lining receives excellent progesterone exposure, but the blood test for progesterone may paradoxically show lower levels than the actual endometrial concentration.
This vaginal route characteristic has an important practical implication: monitoring serum progesterone levels after vaginal supplementation is not a reliable indicator of endometrial progesterone exposure. A low blood progesterone level after vaginal supplementation does not necessarily mean the endometrium is inadequately supported. The two measurements are decoupled.
Common vaginal progesterone preparations include micronized progesterone (Cyclogest, Utrogestan), progesterone gel (Crinone), and compounded progesterone capsules. The dose typically used is 200 to 400 mg two to three times daily, depending on the specific preparation.
Side effects of vaginal progesterone are primarily local — vaginal discharge, mild irritation, and occasionally discomfort with insertion. Systemic side effects are generally mild due to the predominantly local action.
Intramuscular Progesterone — the High-Dose Standard
Intramuscular progesterone — given as an oil-based injection into the buttock or thigh muscle — produces high and sustained systemic progesterone levels. Blood progesterone measurements after intramuscular injections reliably reflect the systemic progesterone concentration, unlike vaginal progesterone.
Intramuscular progesterone was historically the standard luteal support in many IVF protocols, and it remains the preference at some centers and in some clinical situations — particularly where very high systemic progesterone levels are desired, or where poor response to vaginal supplementation is suspected.
The disadvantages of intramuscular progesterone are significant from a patient experience perspective: the injections are uncomfortable, often causing local soreness, induration (hardening), and occasionally sterile abscesses at the injection site. Daily injections over six to twelve weeks are a substantial physical burden for many patients.
Oral Progesterone
Oral micronized progesterone (Utrogestan taken orally) produces significant sedative side effects — drowsiness and sedation — due to the hepatic metabolism of progesterone into sedating neurosteroid metabolites. This limits the dose that can be practically tolerated when taken orally. Oral progesterone is therefore less commonly used as the primary luteal support agent in IVF, though it may be used in combination with vaginal supplementation.
Subcutaneous Progesterone
Subcutaneous progesterone — injected under the skin rather than into muscle — is a newer formulation that offers a middle ground between vaginal and intramuscular routes. Subcutaneous progesterone aqueous solutions (such as Prolutex / Lubion) produce sustained systemic progesterone levels with a simpler injection technique and significantly less local discomfort than intramuscular injections. This preparation is increasingly used in centers that prefer measurable systemic progesterone levels without the injection site complications of intramuscular administration.
When Does Progesterone Supplementation Start?
The timing of progesterone initiation is precisely coordinated with the timing of the embryo transfer — because the progesterone must have been present for the right duration to open the endometrial receptivity window at exactly the time of transfer.
In a fresh IVF transfer cycle, progesterone supplementation typically begins on the evening of or the day after egg retrieval — approximately three to five days before the blastocyst transfer. This timing replicates the natural luteal phase, in which progesterone rises after ovulation and the receptivity window opens on approximately day five after ovulation — corresponding to the developmental age of a blastocyst embryo.
In a frozen embryo transfer cycle using artificial endometrial preparation, progesterone is started after the endometrium has been primed with estrogen for sufficient duration — typically after eight to fourteen days of estrogen, when the lining has reached appropriate thickness and pattern on ultrasound monitoring. The blastocyst transfer then occurs five to six days after progesterone initiation — corresponding precisely to the opening of the implantation window.
In an ERA-guided transfer cycle, the progesterone start date is adjusted based on the ERA result — which identifies the specific timing of the individual patient's receptive window — and the transfer is scheduled at the personalized window rather than at the standard assumed timing.
How Long Should Progesterone Supplementation Continue?
The duration of progesterone supplementation is one of the most commonly asked questions after an IVF cycle — and the answer has evolved as the clinical evidence base has matured.
If the pregnancy test is negative: Progesterone supplementation is discontinued. The endometrium, deprived of progesterone support, will shed over the following days, producing a withdrawal bleed similar to a period.
If the pregnancy test is positive: Progesterone supplementation continues — typically through the first trimester, until the placenta has matured sufficiently to take over progesterone production autonomously. This transition — called luteoplasental shift — occurs approximately at ten to twelve weeks of gestation.
The specific duration of supplementation in a positive cycle — and when it is safe to taper and discontinue — is determined by the treating doctor based on the hCG trajectory, the ultrasound findings, and the overall clinical picture of the early pregnancy. There is no single universal endpoint — decisions are individualized.
A critical caution: Stopping progesterone supplementation prematurely — before the luteoplasental shift is complete and before the doctor has advised discontinuation — carries a risk of early pregnancy loss in cycles where the pregnancy is entirely dependent on the supplemented progesterone. This risk is most relevant in artificial FET cycles (where there is no corpus luteum at all to provide any natural progesterone backup) and in any patient with a compromised luteal phase. Progesterone supplementation should never be discontinued without medical advice — even if a patient finds the daily medication burdensome or interprets early pregnancy symptoms as evidence that supplementation is no longer needed.
Progesterone Levels During the Two-Week Wait
Many patients ask whether their progesterone level can be measured during the two-week wait to assess whether the supplementation is working. The answer depends on which progesterone preparation is being used.
For patients on intramuscular or subcutaneous progesterone, serum progesterone measurements reflect the systemic concentration delivered by the injection and are clinically meaningful. A progesterone level significantly below the target range (typically 10 to 20 ng/mL or above, depending on the protocol) in these patients may prompt a dose adjustment.
For patients on vaginal progesterone, serum levels are unreliable indicators of endometrial exposure due to the first uterine pass effect described earlier. A low serum progesterone in a patient on vaginal supplementation does not reliably indicate inadequate endometrial support. At Metro IVF, the decision about whether to monitor progesterone levels during the luteal phase is individualized based on the preparation being used and the specific clinical circumstances.
The Critical Role of Compliance
The practical importance of taking progesterone supplementation exactly as prescribed — at the right times, in the right dose, without missed doses — cannot be overstated.
In a fresh transfer cycle, the compromised luteal function of the post-retrieval period means that the supplemented progesterone is essential to maintain the endometrial environment. Missing doses or taking doses late reduces endometrial progesterone exposure at a time when consistency matters.
In an artificial FET cycle, the entire luteal phase is artificially created. There is no corpus luteum providing any backup progesterone. Every dose of supplementation is clinically meaningful.
If a dose is missed — particularly in an artificial FET cycle — the patient should contact the Metro IVF team immediately rather than simply doubling the next dose or waiting until the next scheduled dose. The clinical team will advise on the appropriate response, which depends on which dose was missed, how much time has elapsed, and what preparation is being used.
Your Next Step
Progesterone is not a peripheral medication taken out of caution. It is a clinically essential component of IVF success — supporting the endometrial environment, maintaining the implantation window, and in many cycles providing the entire luteal phase support that the body's own compromised post-retrieval function cannot supply.
Understanding why you are taking it — and taking it exactly as prescribed — is part of the informed participation in your own treatment that makes IVF outcomes as good as they can be.
If you are preparing for an IVF cycle and want to understand all of the components of your post-transfer protocol — including the specific progesterone preparation and dose that is right for your situation — a consultation with Dr. Ashish Soni at Metro IVF in Ambikapur provides that individualized clinical guidance.
Metro IVF Test Tube Baby Center Ambikapur, Chhattisgarh metrofertility.in Led by Dr. Ashish Soni — North India's First Fertility Super Specialist
Every component of your IVF protocol matters — including the progesterone. Book your consultation with Dr. Ashish Soni at Metro IVF today.